Biosimilars – Page 4

Biosimilar immunogenicity risk signal during stability pull comparisons: how to handle outliers and statistics without triggering inspection findings

Identifying symptoms of immunogenicity risk signals promptly is essential in ensuring that the quality and safety of biosimilars are not compromised. Symptoms may include:Click to read the full article.

Biosimilar comparability package deficiency after cell line or upstream change: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying symptoms is the first step in addressing a comparability package deficiency. Some common signals may include:Click to read the full article.

Biosimilar method transfer failure across labs during CPV trending review: decision tree for lab method variability vs true product differences

Identifying the right symptoms is the first step in addressing biosimilar method transfer failures. Clinicians and laboratory technicians may observe discrepancies during stability testing, potency assays, or bioanalytical methods that…

Biosimilar regulatory deficiency during review during comparability protocol execution: bridging study planning and regulatory communication strategy

The first step in addressing a biosimilar regulatory deficiency is recognizing the signals that indicate a deviation may have occurred during the comparability protocol execution. Symptoms can manifest in several…

Biosimilar immunogenicity risk signal after downstream resin change: bridging study planning and regulatory communication strategy

Identifying the right symptoms is fundamental in any investigation. In the case of immunogenicity following a change in downstream resin, common signals might include:Click to read the full article.

Analytical similarity failure (Tier 1 CQAs) during FDA/EMA scientific advice / meetings: FDA/EMA expectations for root cause, rework, and comparability justification

Symptoms of analytical similarity failure may first become apparent through various signals during routine quality control or during stability studies. Recognizing these symptoms early is critical. Common symptoms include:Click to…

Biosimilar lot-to-lot variability trend (OOT) after cell line or upstream change: FDA/EMA expectations for root cause, rework, and comparability justification

Recognizing symptoms early in the manufacturing process is crucial to address lot-to-lot variability effectively. Common signals may include:Click to read the full article.

Biosimilar charge variant profile drift during FDA/EMA scientific advice / meetings: how to build a defensible similarity narrative with data integrity controls

In the context of biosimilar production, charge variant profile drift can manifest through a variety of signals, which should be systematically monitored to ensure product quality and regulatory compliance. Notable…

Biosimilar lot-to-lot variability trend (OOT) during comparability protocol execution: how to handle outliers and statistics without triggering inspection findings

The first step in addressing biosimilar lot-to-lot variability trends during comparability execution is to identify the symptoms or signals that indicate an out-of-trend (OOT) occurrence. Symptoms can manifest in multiple…

Biosimilar reference standard qualification gap during CPV trending review: how to handle outliers and statistics without triggering inspection findings

Recognizing signals that indicate potential qualification gaps during CPV trending reviews is the first step in managing deviations effectively. Common symptoms include:Click to read the full article.

Biosimilar lot-to-lot variability trend (OOT) during biosimilar development: inspection-ready evidence pack for comparability and lifecycle management

The first step in any investigation of biosimilar lot-to-lot variability is identifying the symptoms or signals that indicate a potential issue. Symptoms may arise during routine testing, stability studies, or…

Biosimilar process change without bridging study after cell line or upstream change: risk assessment for critical quality attributes and clinical impact

Detecting deviations early is vitally important in pharmaceutical manufacturing, especially for biosimilars where the expected similarity is crucial for efficacy and safety. Symptoms of a problematic process change may manifest…